HomeSVA • NASDAQ
add
Sinovac Biotech Ltd
Previous close
$6.47
Year range
$22.40 - $28.18
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2023info | Y/Y change |
---|---|---|
Revenue | 70.20M | -88.42% |
Operating expense | 191.24M | 12.14% |
Net income | 8.46M | -96.51% |
Net profit margin | 12.05 | -69.85% |
Earnings per share | — | — |
EBITDA | -173.73M | -150.20% |
Effective tax rate | 52.82% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 11.07B | -6.56% |
Total assets | 13.73B | -8.90% |
Total liabilities | 1.49B | 53.07% |
Total equity | 12.24B | — |
Shares outstanding | 99.58M | — |
Price to book | 0.07 | — |
Return on assets | -3.92% | — |
Return on capital | -4.30% | — |
Cash Flow
Net change in cash
(USD) | Jun 2023info | Y/Y change |
---|---|---|
Net income | 8.46M | -96.51% |
Cash from operations | -20.00M | 95.05% |
Cash from investing | -1.37B | 23.82% |
Cash from financing | 108.58M | 1,755.94% |
Net change in cash | -1.32B | 44.46% |
Free cash flow | -139.00M | -251.49% |
About
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Wikipedia
CEO
Founded
2001
Website
Employees
3,558